Repurchases of shares by Concentric AB during week 1, 2024
REDDITCH,
The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of
Concentric shares have been repurchased as follows:
Date: | Aggregated daily volume (number of shares): | Weighted average share price per day (SEK): | Total daily transaction value (SEK): |
3,032 | 178.3667 | 540,807.83 | |
3,702 | 174.2645 | 645,127.18 | |
4,788 | 171.1921 | 819,667.77 | |
4,107 | 169.8413 | 697,538.22 | |
Total accumulated over week 1/2024 | 15,629 | 172.9567 | 2,703,141.01 |
Total accumulated during the repurchase program | 15,629 | 172.9567 | 2,703,141.01 |
All acquisitions have been carried out on Nasdaq
A full breakdown of the transactions is attached to this announcement.
For further information, please contact
This information is information that Concentric AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at
The following files are available for download:
Release | |
https://mb.cision.com/Public/1643/3905140/8d734f840af244a3.pdf | Concentric Transactions 20240102 to 20240105 |
View original content:https://www.prnewswire.com/news-releases/repurchases-of-shares-by-concentric-ab-during-week-1-2024-302029354.html
SOURCE Concentric AB
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACG Metals Achieves First Copper Concentrate Production at Gediktepe
- ADM Club Digitises the Renaissance Court Model Through a Bespoke Technology Stack for Independent Luxury and High Affinity Audiences
- EFICAS Study Results Confirm the Clinical Performance of the Aeson® Total Artificial Heart as a Bridge-to-Transplant Therapy
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share